BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, Grainville T, Bellissant E, Siproudhis L, Bouguen G. Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. Clin Gastroenterol Hepatol 2021;19:288-295.e4. [PMID: 32200087 DOI: 10.1016/j.cgh.2020.03.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Dreesen E. Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues. Current Opinion in Pharmacology 2020;55:53-9. [DOI: 10.1016/j.coph.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Faelens R, Wang Z, Bouillon T, Declerck P, Ferrante M, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics 2021;13:1623. [PMID: 34683916 DOI: 10.3390/pharmaceutics13101623] [Reference Citation Analysis]
3 Bouguen G, Brunet T. Reply. Clin Gastroenterol Hepatol 2021;19:855-6. [PMID: 33249012 DOI: 10.1016/j.cgh.2020.06.013] [Reference Citation Analysis]
4 Petitcollin A, Bouguen G. Reply. Clin Gastroenterol Hepatol 2021;19:2458-9. [PMID: 33249015 DOI: 10.1016/j.cgh.2020.07.001] [Reference Citation Analysis]
5 Kuhnel L, Hawley CM, Johnson DW, Gobe GC, Ellis RJ, Francis RS. Allograft failure in kidney transplant recipients who developed kidney failure secondary to ANCA-associated vasculitis. Clin Transplant 2021;35:e14235. [PMID: 33527568 DOI: 10.1111/ctr.14235] [Reference Citation Analysis]
6 Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021. [PMID: 34388143 DOI: 10.14309/ajg.0000000000001396] [Reference Citation Analysis]
7 Truffot A, Gautier-Veyret E, Baillet A, Jourdil JF, Stanke-Labesque F, Gottenberg JE. Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundam Clin Pharmacol 2021;35:1090-9. [PMID: 33638167 DOI: 10.1111/fcp.12662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World J Gastroenterol 2022; 28(9): 961-972 [DOI: 10.3748/wjg.v28.i9.961] [Reference Citation Analysis]
9 Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, Vermeire S, Ferrante M, Dreesen E. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2021;87:3776-89. [PMID: 33604964 DOI: 10.1111/bcp.14785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021;19:854-5. [PMID: 33248082 DOI: 10.1016/j.cgh.2020.04.088] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, Schwab M, Lehr T. External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021;13:1368. [PMID: 34575443 DOI: 10.3390/pharmaceutics13091368] [Reference Citation Analysis]
12 Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-biroulet L. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology & Hepatology 2022;7:171-85. [DOI: 10.1016/s2468-1253(21)00223-5] [Reference Citation Analysis]
13 Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. Clin Transl Gastroenterol 2021;12:e00380. [PMID: 34228004 DOI: 10.14309/ctg.0000000000000380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Con D, Van Langenberg DR, Vasudevan A. Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection. Clin Gastroenterol Hepatol 2021;19:1077. [PMID: 33249017 DOI: 10.1016/j.cgh.2020.05.057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Murdaca G, Noberasco G, Battaglini A, Vassallo C, Giusti F, Greco M, Schiavi C, Sticchi L, Icardi G, Orsi A. Systemic Sclerosis and Vaccinations: A Register-Based Cohort Study about Seasonal Influenza and Streptococcus pneumoniae Vaccination Rate and Uptake from Liguria Regional Center, Northwest Italy. Vaccines (Basel) 2020;8:E204. [PMID: 32354027 DOI: 10.3390/vaccines8020204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]